KALVISTA PHARMACEUTICALS INC's ticker is KALV and the CUSIP is 483497103. A total of 92 filers reported holding KALVISTA PHARMACEUTICALS INC in Q4 2022. The put-call ratio across all filers is 0.09 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $712,620 | -10.6% | 74,000 | -16.5% | 0.00% | 0.0% |
| Q2 2023 | $797,400 | -1.0% | 88,600 | -13.6% | 0.00% | 0.0% |
| Q1 2023 | $805,650 | +0.7% | 102,500 | -13.4% | 0.00% | -33.3% |
| Q4 2022 | $799,708 | -6.9% | 118,300 | +99.7% | 0.00% | 0.0% |
| Q3 2022 | $859,000 | +17.3% | 59,229 | -20.4% | 0.00% | +50.0% |
| Q2 2022 | $732,000 | +46.4% | 74,400 | +119.5% | 0.00% | +100.0% |
| Q1 2022 | $500,000 | +76.7% | 33,900 | +58.4% | 0.00% | 0.0% |
| Q4 2021 | $283,000 | -54.3% | 21,400 | -39.7% | 0.00% | 0.0% |
| Q3 2021 | $619,000 | -19.0% | 35,500 | +11.3% | 0.00% | -50.0% |
| Q2 2021 | $764,000 | -6.8% | 31,900 | 0.0% | 0.00% | 0.0% |
| Q1 2021 | $820,000 | +113.0% | 31,900 | +57.1% | 0.00% | +100.0% |
| Q4 2020 | $385,000 | +23.4% | 20,300 | +16.0% | 0.00% | 0.0% |
| Q4 2019 | $312,000 | +53.7% | 17,500 | 0.0% | 0.00% | 0.0% |
| Q3 2019 | $203,000 | – | 17,500 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SV Health Investors, LLC | 1,719,576 | $25,679,000 | 12.37% |
| Vivo Capital, LLC | 1,618,296 | $30,731,000 | 1.37% |
| Opaleye Management Inc. | 470,203 | $8,929,000 | 1.17% |
| INTERWEST VENTURE MANAGEMENT CO | 388,766 | $7,383,000 | 0.92% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 177,433 | $3,369,000 | 0.92% |
| Ikarian Capital, LLC | 1,063,961 | $20,204,000 | 0.89% |
| Ghost Tree Capital, LLC | 200,000 | $3,798,000 | 0.85% |
| Logos Global Management LP | 490,000 | $9,305,000 | 0.80% |
| Eventide Asset Management | 1,680,000 | $31,903,000 | 0.49% |
| Affinity Asset Advisors, LLC | 45,000 | $855,000 | 0.45% |